Page 8 - Market Commitment News Today

Moderna plots vaccines against 15 pathogens with future pandemic potential

Moderna Inc said on Monday (March 7) it plans to develop and begin testing vaccines targeting 15 of the world's most worrisome pathogens by 2025 and will permanently wave its Covid-19 vaccine patents for shots intended for certain low- and middle-income countries. The US biotechnology company also said it will make its messenger RNA (mRNA) technology available to researchers working...

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its global public health strategy through four new initiatives aimed at advancing mRNA vaccines for the prevention of infectious diseases. First, Moderna is announcing a commitment to ...

MODERNA ANNOUNCES ITS GLOBAL PUBLIC HEALTH STRATEGYMARCH 07, 2022Moderna announces commitment to advance vaccines targeting 15 pathogens identified as biggest public health risk by WHO and CEPI into clinical studies by 2025Moderna launches mRNA Access, a new collaborative enabling researchers around the world to uti...

Moderna said on Monday it plans to develop and begin testing vaccines targeting 15 of the worlds most worrisome pathogens by 2025.

If vaccine diplomacy is the new great game, it is being played wrong by all sides, with the risk that no one will be left a winner. Originally published in The Diplomat.

AKP

Moderna and Adium Pharma have entered a distribution service agreement to commercialise the former’s Covid-19 vaccine in Latin America.

Press release content from Accesswire. The AP news staff was not involved in its creation.

Moderna has a commercial footprint in 56 countries across the world through direct presence and distributors and plans expansion in ten additional markets in 2022Moderna also supplies the Company's COVID-19